Clinical Trial Detail

NCT ID NCT03847649
Title Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Toxicity
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

Advanced Solid Tumor

Therapies

Durvalumab

Durvalumab + Prednisone

Age Groups: adult senior

No variant requirements are available.